Herndon Jill Boylston, Aravamudhan Krishna, Stephenson Ronald L, Brandon Ryan, Ruff Jesley, Catalanotto Frank, Le Huong
Key Analytics and Consulting, LLC, Gainesville, Florida, USA (Dr Herndon was with the Department of Health Outcomes and Policy, University of Florida College of Medicine, Gainesville, Florida, USA, when this study was conducted).
Dental Quality Alliance, American Dental Association, Chicago, Illinois, USA.
J Am Med Inform Assoc. 2017 May 1;24(3):503-512. doi: 10.1093/jamia/ocw137.
To describe the stakeholder-engaged processes used to develop, specify, and validate 2 oral health care electronic clinical quality measures.
A broad range of stakeholders were engaged from conception through testing to develop measures and test feasibility, reliability, and validity following National Quality Forum guidance. We assessed data element feasibility through semistructured interviews with key stakeholders using a National Quality Forum-recommended scorecard. We created test datasets of synthetic patients to test measure implementation feasibility and reliability within and across electronic health record (EHR) systems. We validated implementation with automated reporting of EHR clinical data against manual record reviews, using the kappa statistic.
A stakeholder workgroup was formed and guided all development and testing processes. All critical data elements passed feasibility testing. Four test datasets, representing 577 synthetic patients, were developed and implemented within EHR vendors' software, demonstrating measure implementation feasibility. Measure reliability and validity were established through implementation at clinical practice sites, with kappa statistic values in the "almost perfect" agreement range of 0.80-0.99 for all but 1 measure component, which demonstrated "substantial" agreement. The 2 validated measures were published in the United States Health Information Knowledgebase.
The stakeholder-engaged processes used in this study facilitated a successful measure development and testing cycle. Engaging stakeholders early and throughout development and testing promotes early identification of and attention to potential threats to feasibility, reliability, and validity, thereby averting significant resource investments that are unlikely to be fruitful.
描述用于制定、明确和验证2项口腔保健电子临床质量指标的利益相关方参与过程。
从指标概念形成到测试阶段,广泛吸纳了各类利益相关方,以按照美国国家质量论坛的指导制定指标并测试其可行性、可靠性和有效性。我们通过使用美国国家质量论坛推荐的记分卡,对关键利益相关方进行半结构化访谈,评估数据元素的可行性。我们创建了合成患者测试数据集,以测试电子健康记录(EHR)系统内部及跨系统的指标实施可行性和可靠性。我们使用kappa统计量,通过对EHR临床数据的自动报告与人工病历审查进行对比,验证指标的实施情况。
成立了一个利益相关方工作组,指导所有的开发和测试过程。所有关键数据元素均通过了可行性测试。在EHR供应商的软件中开发并实施了4个代表577名合成患者的测试数据集,证明了指标实施的可行性。通过在临床实践地点的实施,建立了指标的可靠性和有效性,除1个指标组件外,所有指标组件的kappa统计量值在“几乎完美”的一致性范围内,为0.80 - 0.99,该组件显示为“实质性”一致。这2项经过验证的指标已在美国健康信息知识库中发布。
本研究中使用的利益相关方参与过程促进了指标开发和测试的成功循环。在整个开发和测试过程中尽早让利益相关方参与,有助于早期识别并关注对可行性、可靠性和有效性的潜在威胁,从而避免投入不太可能有成效的大量资源。